⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RVMD News
Revolution Medicines, Inc. Common Stock
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer
globenewswire.com
RVMD
Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers
accessnewswire.com
ACTU
RVMD
ERAS
Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
globenewswire.com
RVMD
Form 8-K
sec.gov
RVMDW
RVMD
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
globenewswire.com
RVMD
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
globenewswire.com
RVMD
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
globenewswire.com
RVMD
Molecular Glues Competitive Landscape Research Report 2026: Comprehensive Insights About 80+ Companies and 90+ Drugs
globenewswire.com
BMY
RVMD
NRIX
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
globenewswire.com
RVMD
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
globenewswire.com
RVMD